Patents by Inventor Elena Sabrina Reckzeh

Elena Sabrina Reckzeh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of glucose transporters (GLUTs)
    Patent number: 12060362
    Abstract: The present invention relates to 2,6-methanobenzo[g][1]oxacin-4-one compounds and their analog compounds and pharmaceutically acceptable salts thereof as selective inhibitor of glucose transporters 1 and 3 (GLUTs 1 and 3), to methods of preparing said compounds, and to the use thereof as pharmaceutically active agents, especially for the prophylaxis and/or treatment of metabolic diseases, immunological diseases, autoimmune diseases, inflammation, graft versus host disease, cancer, and metastasis thereof. Furthermore, the present invention is directed to pharmaceutical composition comprising at least one of 2,6-methanobenzo[g][1]oxacin-4-one compounds and their analog compounds.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: August 13, 2024
    Assignees: LEAD DISCOVERY CENTER GMBH, MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Herbert Waldmann, Gunther Zischinsky, Peter Nussbaumer, Slava Ziegler, Melanie Schwalfenberg, Javier de Ceballos Cerrajeria, Elena Sabrina Reckzeh, George Karageorgis
  • INHIBITORS OF GLUCOSE TRANSPORTERS (GLUTs)
    Publication number: 20210198269
    Abstract: The present invention relates to 2,6-methanobenzo[g][l]oxacin-4-onecompounds and their analog compounds and pharmaceutically acceptable salts thereof as selective inhibitor of glucose transporters 1 and 3 (GLUTs 1 and 3), to methods of preparing said compounds, and to the use thereof as pharmaceutically active agents, especially for the prophylaxis and/or treatment of metabolic diseases, immunological diseases, autoimmune diseases, inflammation, graft versus host disease, cancer, and metastasis thereof. Furthermore, the present invention is directed to pharmaceutical composition comprising at least one of 2,6-methanobenzo[g][l]oxacin-4-one compounds and their analog compounds.
    Type: Application
    Filed: September 5, 2019
    Publication date: July 1, 2021
    Inventors: Herbert Waldmann, Gunther Zischinsky, Peter Nussbaumer, Slava Ziegler, Melanie Schwalfenberg, Javier de Ceballos Cerrajeria, Elena Sabrina Reckzeh, George Karageorgis